Quick Answer
Spero Therapeutics, Inc. reported Research And Development Expense of $38.47 million for the year ending 2025.
- Spero Therapeutics, Inc. showed a decrease of -60.2% in Research And Development Expense from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $6.01 million | Q1 2017: $6.00 million | Q2 2017: $7.46 million | Q3 2017: $6.91 million | Q1 2018: $8.93 million | Q2 2018: $7.37 million | Q3 2018: $8.46 million | Q1 2019: $9.53 million | Q2 2019: $12.03 million | Q3 2019: $18.50 million | Q1 2020: $20.44 million | Q2 2020: $15.66 million | Q3 2020: $17.71 million | Q1 2021: $18.40 million | Q2 2021: $14.46 million | Q3 2021: $14.44 million | Q1 2022: $16.97 million | Q2 2022: $8.17 million | Q3 2022: $7.36 million | Q1 2023: $8.98 million | Q2 2023: $9.51 million | Q3 2023: $16.39 million | Q1 2024: $17.33 million | Q2 2024: $23.73 million | Q3 2024: $26.86 million | Q1 2025: $13.61 million | Q2 2025: $10.67 million | Q3 2025: $8.60 million.
- Over the full 11 years of available data (2015 to 2025), Spero Therapeutics, Inc.'s Research And Development Expense has grown by 245.8%.
- Historical annual values: Fiscal year 2025: $38.47 million | Fiscal year 2024: $96.76 million | Fiscal year 2023: $51.44 million | Fiscal year 2022: $47.59 million | Fiscal year 2021: $64.53 million | Fiscal year 2020: $67.00 million | Fiscal year 2019: $65.78 million | Fiscal year 2018: $33.89 million | Fiscal year 2017: $32.87 million | Fiscal year 2016: $26.33 million | Fiscal year 2015: $11.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: